Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from managed care entities. These insurers are https://larakvau382834.blogdal.com/42445847/the-vyndamax-faces-is-dealing-with-pbm-challenges-the-look-at-reimbursement-battles